Editor’s note: Discover the most recent COVID-19 news and guidance in Medscape’s Coronavirus Resource Center
.
On the suggestions of its independent information keeping track of committee (DMC), the HEALING trial has stopped recruitment to the colchicine arm for lack of efficacy in patients hospitalized with COVID-19
” The DMC saw no persuading evidence that further recruitment would offer definitive evidence of rewarding mortality benefit either general or in any pre-specified subgroup,” the British private investigators revealed today.
” The RECOVERY trial has actually already determined 2 anti-inflammatory drugs– dexamethasone and tocilizumab— that improve the chances of survival for patients with extreme COVID-19 It is frustrating that colchicine, which is widely used to treat gout and other inflammatory conditions, has no result in these patients,” cochief investigator Martin Landray, MB ChB, PhD, stated in a declaration.
” We do big, randomized trials to establish whether a drug that seems promising in theory has genuine benefits for patients in practice. Colchicine is not one of those,” said Landry, University of Oxford, United Kingdom.
The HEALING trial is assessing a series of potential treatments for COVID-19 at 180 health centers in the UK, Indonesia, and Nepal, and was designed with the expectation that drugs would be included or dropped as the evidence changes. Given That November 2020, the trial has included an arm comparing colchicine to usual care alone.
As part of a routine conference March 4, the DMC examined data from an initial analysis based upon 2178 deaths amongst 11,162 patients, 94%of whom were being treated with a corticosteroid such as dexamethasone.
The outcomes revealed no considerable distinction in the primary endpoint of 28- day death in patients randomized to colchicine vs typical care alone (20%vs 19%; threat ratio, 1.02; 95%CI, 0.94 – 1.11; P =.63).
Follow-up is continuous and outcomes will be published as quickly as possible, the investigators say. So far, they keep in mind, there has actually been no persuading proof of a result of colchicine on scientific outcomes in hospitalized COVID-19 patients.
Recruitment will continue to all other treatment arms– aspirin, baricitinib, Regeneron’s antibody mixed drink, and, in select healthcare facilities, dimethyl fumarate— the investigators state.
Cochief investigator Peter Hornby, MD, PhD, likewise from the University of Oxford, noted that this has been the largest trial ever of colchicine. “Whilst we are dissatisfied that the overall result is unfavorable, it is still important details for the future care of patients in the UK and worldwide.”
Follow Patrice Wendling on Twitter: @pwendl Medscape Cardiology, join us on Twitter and Facebook
No comments:
Post a Comment